Login Register Cart 0
Generic placeholder image

Current Clinical Pharmacology

Editor-in-Chief

ISSN (Print): 1574-8847
ISSN (Online): 2212-3938

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Commentary

Why are there Variations in the Responses of Glucagon-like Peptide-1 Agonists among the Type 2 Diabetic Patients?

Author(s): Thekkuttuparambil A. Ajith*

Volume 14, Issue 3, 2019

Page: [247 - 248] Pages: 2

DOI: 10.2174/157488471403191231143537

Open Access Journals Promotions 2
« Previous Next »
[1]
World Health Organization. diagnosis and classification of diabetes mellitus and its complications Part 1: Diagnosis and classification of diabetes mellitus WHO/NCD/NCS/99 2ed Geneva.. 1999.
[2]
Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27(5): 1047-53.
[http://dx.doi.org/10.2337/diacare.27.5.1047] [PMID: 15111519]
[3]
Batsakis S. Diabetes mellitus and its treatment. Int J Diabetes Metab 2005; 13: 111-34.
[http://dx.doi.org/10.1159/000497580]
[4]
Whirl-Carrillo M, McDonagh EM, Hebert JM, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 2012; 92(4): 414-7.
[http://dx.doi.org/10.1038/clpt.2012.96] [PMID: 22992668]
[5]
Maruthur NM, Gribble MO, Bennett WL, et al. The pharmacogenetics of type 2 diabetes: A systematic review. Diabetes Care 2014; 37(3): 876-86.
[http://dx.doi.org/10.2337/dc13-1276] [PMID: 24558078]
[6]
Nauck MA, Baller B, Meier JJ. Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. Diabetes 2004; 53(Suppl. 3): S190-6.
[http://dx.doi.org/10.2337/diabetes.53.suppl_3.S190] [PMID: 15561910]
[7]
Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87(4): 1409-39.
[http://dx.doi.org/10.1152/physrev.00034.2006] [PMID: 17928588]
[8]
Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001; 50(3): 609-13.
[http://dx.doi.org/10.2337/diabetes.50.3.609] [PMID: 11246881]
[9]
Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001; 86(8): 3717-23.
[http://dx.doi.org/10.1210/jcem.86.8.7750] [PMID: 11502801]
[10]
Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132(6): 2131-57.
[http://dx.doi.org/10.1053/j.gastro.2007.03.054] [PMID: 17498508]
[11]
Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3(3): 153-65.
[http://dx.doi.org/10.1016/j.cmet.2006.01.004] [PMID: 16517403]
[12]
Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000; 43(9): 1664-9.
[http://dx.doi.org/10.1021/jm9909645] [PMID: 10794683]
[13]
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38(1): 140-9.
[http://dx.doi.org/10.2337/dc14-2441] [PMID: 25538310]
[14]
Karras SN, Rapti E, Koufakis T, Kyriazou A, Goulis DG, Kotsa K. Pharmacogenetics of glucagon-like peptide-1 agonists for the treatment of type 2 diabetes mellitus. Curr Clin Pharmacol 2017; 12(4): 202-9.
[http://dx.doi.org/10.2174/1574884713666180221121512] [PMID: 29473524]
[15]
Tkáč I, Gotthardová I. Pharmacogenetic aspects of the treatment of Type 2 diabetes with the incretin effect enhancers. Pharmacogenomics 2016; 17(7): 795-804.
[http://dx.doi.org/10.2217/pgs-2016-0011] [PMID: 27166975]
[16]
Koole C, Wootten D, Simms J, et al. Polymorphism and ligand dependent changes in human glucagon-like peptide-1 receptor (GLP-1R) function: Allosteric rescue of loss of function mutation. Mol Pharmacol 2011; 80(3): 486-97.
[http://dx.doi.org/10.1124/mol.111.072884] [PMID: 21616920]
[17]
Beinborn M, Worrall CI, McBride EW, Kopin AS. A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness. Regul Pept 2005; 130(1-2): 1-6.
[http://dx.doi.org/10.1016/j.regpep.2005.05.001] [PMID: 15975668]
[18]
Tokuyama Y, Matsui K, Egashira T, Nozaki O, Ishizuka T, Kanatsuka A. Five missense mutations in glucagon-like peptide 1 receptor gene in Japanese population. Diabetes Res Clin Pract 2004; 66(1): 63-9.
[http://dx.doi.org/10.1016/j.diabres.2004.02.004] [PMID: 15364163]
[19]
Sathananthan A, Man CD, Micheletto F, et al. Common genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects: A pilot study. Diabetes Care 2010; 33(9): 2074-6.
[http://dx.doi.org/10.2337/dc10-0200] [PMID: 20805279]
[20]
Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenomics of oral antidiabetic medications: Current data and pharmacoepigenomic perspective. Pharmacogenomics 2011; 12(8): 1161-91.
[http://dx.doi.org/10.2217/pgs.11.65] [PMID: 21843065]

Rights & Permissions Print Cite
Article Metrics
28
5
© 2024 Bentham Science Publishers | Privacy Policy